Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Urinary Tract Calculi III: Medical Management

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...

Urinary Tract Calculi IV: Nutrition Therapy and Prevention

Urinary Tract Calculi IV: Nutrition Therapy and Prevention

Management of renal calculi focuses on effective strategies like tailored nutrition and hydration therapy. Adjusting diet and fluid intake reduces stone formation and recurrence, making these interventions simple yet powerful in kidney stone prevention and management.Understanding Kidney StonesKidney stones form when calcium, oxalate, uric acid, and cystine concentrate and crystallize in urine. Factors contributing to their formation include genetic predisposition, certain medical conditions,...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Peptic Ulcer Disease IV: Management

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

OMERACT 2020: A virtual (R)evolution.

Seminars in arthritis and rheumatism·2021

Same author

Experience and impact of crystal pyrophosphate deposition (CPPD) from a patient and caregiver perspective: A qualitative exploration from the OMERACT CPPD working group.

Seminars in arthritis and rheumatism·2021

Same author

Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) common language definition of gout.

RMD open·2021

Same author

Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach.

Seminars in arthritis and rheumatism·2021

Same author

OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods study.

Seminars in arthritis and rheumatism·2021

Same author

Epidemiology and Outcomes of Alcohol Use Hospitalizations in People With Gout, Rheumatoid Arthritis, Fibromyalgia, Osteoarthritis, or Low Back Pain: A National US Study.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2021

Search research articles

Related Experiment Video

Updated: May 17, 2026

Tuina Intervention in Sodium Monoiodoacetate Injection-Induced Rat Model of Knee Osteoarthritis

Tuina Intervention in Sodium Monoiodoacetate Injection-Induced Rat Model of Knee Osteoarthritis

Published on: January 12, 2024

Emerging therapies for gout.

Jasvinder A Singh¹

¹Medicine Service and Center for Surgical Medical Acute Care Research and Transitions, Birmingham VA Medical Center, Birmingham, AL, USA. Jasvinder.md@gmail.com

Expert Opinion on Emerging Drugs

|November 7, 2012

Summary

New gout treatments are emerging, targeting inflammation with interleukin-1 inhibitors like rilonacept and canakinumab, and increasing urate excretion with drugs such as lesinurad. These advancements aim to improve gout management and patient outcomes.

Area of Science:

Rheumatology
Immunology
Pharmacology

Background:

Gout is a prevalent inflammatory arthritis affecting 4% of the US adult population.
It causes significant joint pain, inflammation, and acute flares, leading to disability and reduced quality of life.
Chronic, untreated gout can result in joint destruction, chronic pain, and functional decline.

Purpose of the Study:

To discuss emerging therapeutic strategies for gout management.
To highlight novel approaches targeting both acute inflammation and underlying urate levels.

Main Methods:

Review of preclinical and clinical therapeutic strategies for gout.
Discussion of targeted therapies including interleukin-1 inhibitors and urate-excreting agents.

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Related Experiment Videos

Last Updated: May 17, 2026

Tuina Intervention in Sodium Monoiodoacetate Injection-Induced Rat Model of Knee Osteoarthritis

Tuina Intervention in Sodium Monoiodoacetate Injection-Induced Rat Model of Knee Osteoarthritis

Published on: January 12, 2024

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Main Results:

Several new treatments target acute gout flares by inhibiting interleukin-1 (IL-1).
Examples of IL-1 inhibitors include rilonacept and canakinumab.
Emerging strategies also focus on increasing renal urate excretion via agents like lesinurad, which inhibits URAT1.

Conclusions:

Multiple novel treatment options for gout have become available.
These advancements offer expanded therapeutic choices for clinicians and patients.
The goal is to improve the chances of achieving gout remission and better disease control.